{"id":2345,"date":"2016-03-22T11:33:26","date_gmt":"2016-03-22T15:33:26","guid":{"rendered":"https:\/\/medicarereport.org\/?p=2345"},"modified":"2016-03-22T11:33:26","modified_gmt":"2016-03-22T15:33:26","slug":"are-pharmacy-benefit-managers-the-cause-of-high-drug-costs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=2345","title":{"rendered":"Are Pharmacy Benefit Managers the Cause of High Drug Costs?"},"content":{"rendered":"<p>Why are we paying more for drugs; is it due to secret deals between drug makers and pharmacy benefit managers (PBMs)?<\/p>\n<p>A pharmacy benefit manager (PBM) role is to negotiate deals with drug makers that may include rebates and other compensation to encourage certain drugs and have them listed on the insurances\u2019 plans formulary lists. A formulary list is prescription drugs, both generic and brand name, used by practitioners to identify drugs that offer the greatest overall value. \u00a0The Centers of Medicare and Medicaid and lawmakers are considering requiring public disclosure in how PBMs determine reimbursement. \u00a0<a href=\"http:\/\/www.usatoday.com\/story\/news\/nation\/2016\/03\/21\/pharmacy-benefit-firms-can-raise-drug-costs-despite-cheaper-choices\/81767978\/?utm_campaign=KHN%3A+First+Edition&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=27545617&amp;_hsenc=p2ANqtz--9HFwMx8jxbsRv0-13vD7h4gNz2e1yUY2S5iDlC7fYLZQYRAN_RtparDCZSvdCIxANopRieFbMlfr5Xr5Rh__hfmSv1w&amp;_hsmi=27545617\" target=\"_blank\">Read the article here\u2026.<\/a><\/p>\n<p>&nbsp;<\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>Why are we paying more for drugs; is it due to secret deals between drug makers and pharmacy benefit managers<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-2345","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/2345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2345"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/2345\/revisions"}],"predecessor-version":[{"id":2346,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/2345\/revisions\/2346"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}